Appln. No.: 10/588,902

Amendment dated September 3, 2010 Reply to Office Action of March 18, 2010

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

Claims 1-22 (Canceled)

23. (Currently Amended) A compound of formula (I):

wherein

 $R_1$  is optionally substituted  $C_1$ - $C_6$ alkyl  $C_2$ - $C_6$ alkenyl, or  $C_2$ - $C_6$ alkynyl, or  $-NR_6R_7$ .  $-OR_8$ ,  $-SR_9$  or halogen;

R<sub>2</sub> is optionally substituted 5-membered heteroaryl;

 $R_3$  is H; optionally substituted  $C_1$ - $C_6$ alkyl,  $C_2$ - $C_6$ alkenyl,  $C_2$ alkynyl, or  $C_3$ - $C_7$  cycloalkyl, halogen; OH or  $OR_{10}$ ;

R<sub>4</sub> is H, optionally substituted C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>6</sub>alkenyl, C<sub>3</sub>-C<sub>6</sub>alkynyl l, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, aryl or heteroaryl,

R<sub>5</sub> is H or optionally substituted C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>6</sub>alkenyl, C<sub>3</sub>-C<sub>6</sub>alkynyl, or C<sub>3</sub>-C<sub>7</sub>cycloalkyl; or R<sub>4</sub> and R<sub>5</sub> together form a 5 or 6-membered heterocyclic ring;

R<sub>6</sub> is H or optionally substituted C<sub>1</sub>-C<sub>3</sub>alkyl, C<sub>3</sub>-C<sub>6</sub>alkenyl, C<sub>3</sub>-C<sub>6</sub>alkynyl, or C<sub>3</sub>-C<sub>7</sub> cycloalkyl; R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub> and R<sub>10</sub> are optionally substituted C<sub>1</sub>-C<sub>3</sub>alkyl, C<sub>3</sub>-C<sub>6</sub>alkenyl, C<sub>3</sub>-C<sub>6</sub>alkynyl, or C<sub>3</sub>C<sub>7</sub> cycloalkyl or

R<sub>6</sub> and R<sub>7</sub> together form a 5 or 6-membered heterocyclic ring; or a pharmaceutically acceptable salt or prodrug thereof.

Appln. No.: 10/588,902

Amendment dated September 3, 2010 Reply to Office Action of March 18, 2010

- 24. (Original) A compound as claimed in claim 23 wherein the compound is selected from any of the compounds as shown in Table 1.
- 25. (Previously Presented) A therapy comprising administering an effective amount of a compound as claimed in claim 23.
- 26. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 23 in combination with a pharmaceutically acceptable carrier or excipients.

Claims 27-42 (Canceled)